Literature DB >> 25438460

Belimumab for the treatment of refractory systemic lupus erythematosus: real-life experience in the first year of use in 18 Italian patients.

Laura Andreoli, Rossella Reggia, Lara Pea, Micol Frassi, Alessandra Zanola, Stefania Cartella, Franco Franceschini, Angela Tincani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25438460

Source DB:  PubMed          Journal:  Isr Med Assoc J            Impact factor:   0.892


× No keyword cloud information.
  10 in total

1.  Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients.

Authors:  Morton Scheinberg; Flavio Fernando Nogueira de Melo; Adrian Nogueira Bueno; Carolyne Mendes Costa; Maria Lucia Alvares de Azevedo Bahr; Enio Ribeiro Reis
Journal:  Clin Rheumatol       Date:  2016-04-23       Impact factor: 2.980

2.  BAFF level increased in patients with autoimmune hemolytic anemia.

Authors:  Yu-Bing Zhao; Jun-Min Li; Bei-Wen Wei; Zi-Zhen Xu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

Review 3.  B Cell-Based Treatments in SLE: Past Experience and Current Directions.

Authors:  Stamatis-Nick C Liossis; Chrysanthi Staveri
Journal:  Curr Rheumatol Rep       Date:  2017-11-04       Impact factor: 4.592

Review 4.  Belimumab in systemic lupus erythematosus: a perspective review.

Authors:  Joyce S Hui-Yuen; Xiao Q Li; Anca D Askanase
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-08       Impact factor: 5.346

Review 5.  Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus.

Authors:  Tian Yu; Elena Y Enioutina; Hermine I Brunner; Alexander A Vinks; Catherine M Sherwin
Journal:  Clin Pharmacokinet       Date:  2017-02       Impact factor: 6.447

6.  Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.

Authors:  A Schwarting; M A Dooley; D A Roth; L Edwards; A Thompson; B Wilson
Journal:  Lupus       Date:  2016-08-03       Impact factor: 2.911

Review 7.  Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies.

Authors:  Larosa Maddalena; Francesca Trentin; Mariele Gatto; Margherita Zen; Linda Nalotto; Francesca Saccon; Elisabetta Zanatta; Luca Iaccarino; Andrea Doria
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

Review 8.  Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab.

Authors:  Marla Guzman; Joyce S Hui-Yuen
Journal:  Drug Des Devel Ther       Date:  2020-06-25       Impact factor: 4.162

9.  Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA.

Authors:  Christopher F Bell; Julie Priest; Marni Stott-Miller; Hong Kan; Justyna Amelio; Xue Song; Brendan Limone; Virginia Noxon; Karen H Costenbader
Journal:  Lupus Sci Med       Date:  2020-03-26

Review 10.  Real-World Effectiveness of Belimumab in Systemic Lupus Erythematosus: A Systematic Literature Review.

Authors:  Shirley P Huang; Sonya J Snedecor; Sakina Nanji; Emily Lloyd; Christopher F Bell
Journal:  Rheumatol Ther       Date:  2022-05-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.